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Vitamin El NADH:ubiquinone oxidoreductase (complex I), is associated with a variety of
clinical phenotypes such as Leigh syndrome, encephalomyopathy and cardiomyopathy. Circumstantial
evidence suggests that increased reactive oxygen species (ROS) levels contribute to the pathogenesis of these
disorders. Here we assessed the effect of the water-soluble vitamin E derivative Trolox on ROS levels, and the
amount and activity of complex I in ﬁbroblasts of six children with isolated complex I deﬁciency caused by a
mutation in the NDUFS1, NDUFS2, NDUFS7, NDUFS8 or NDUFV1 gene. Patient cells displayed increased ROS
levels and a variable decrease in complex I activity and amount. For control cells, the ratio between activity
and amount was 1 whereas for the patients this ratio was below 1, indicating a defect in intrinsic catalytic
activity of complex I in the latter cells. Trolox treatment dramatically reduced ROS levels in both control and
patient cells, which was paralleled by a substantial increase in the amount of complex I. Although the ratio
between the increase in activity and amount of complex I was exactly proportional in control cells it varied
between 0.1 and 0.8 for the patients. Our ﬁndings suggest that the expression of complex I is regulated by
ROS. Furthermore, they provide evidence that both the amount and intrinsic activity of complex I are
decreased in inherited complex I deﬁciency. The ﬁnding that Trolox treatment increased the amount of
complex I might aid the future development of antioxidant treatment strategies for patients. However, such
treatment may only be beneﬁcial to patients with a relatively small reduction in intrinsic catalytic defect of
the complex.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe oxidative phosphorylation (OXPHOS) system consists of ﬁve
multi-protein complexes (I–V) and is essential for mitochondrial
function [1–3]. OXPHOS deﬁciency is associated with a wide range of
metabolic disorders, age-related diseases and certain forms of cancer
[4–6]. OXPHOS deﬁciency can occur at any given age, but its onset is
usually within the ﬁrst 2 years of life. In 40% of the early-onset cases,
the decrease in OXPHOS activity is associated with an isolated (25%) or
combined (15%) deﬁciency of complex I [2]. Human complex I (NADH:
ubiquinone oxidoreductase; EC 1.6.5.3) consists of 7 mitochondriall electrophoresis; IGA, in-gel
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l rights reserved.DNA-encoded (mtDNA) and 38 nuclear DNA-encoded (nDNA) sub-
units [7]. In the majority of early-onset patients, complex I deﬁciency
(OMIM252010) is caused bymutations in nDNA-encoded subunits [8–
11]. Additionally, disease causing mutations have been found in
nDNA-encoded complex I assembly factors like B17.2 L [12]. Recent
work has shown that disease causing mutations may reduce the
assembly/stability of holo complex I, resulting in a lower rate of NADH
oxidation [13,14]. However, such mutations may also primarily
decrease the intrinsic catalytic activity of the holocomplex [15].
At present, the pathophysiological mechanisms linking defects in
complex I genes to cellular dysfunction and disease are poorly under-
stood. Mutations in nDNA-encoded complex I subunits can alter
mitochondrial shape and induce aberrations in mitochondrial and
cellular Ca2+/ATP handling [16–18]. Furthermore, evidence has been
provided that the production of reactive oxygen species (ROS) is
increased in isolated complex I deﬁciency [14,19–24]. If ROS are not
adequately neutralized by the cell's antioxidant mechanisms, oxida-
tive modiﬁcations of speciﬁc proteins may occur [25]. The latter may
ultimately contribute to OXPHOS dysfunction. In-vitro assays with the
ﬂavoprotein fraction of bovine complex I revealed that NADH-induced
superoxide production can cause speciﬁc oxidative modiﬁcations of
the 51-kDa (NDUFV1) subunit, resulting in a decrease in electron
Table 1
Control and patient ﬁbroblasts
Cell linea Mutated subunit Mutationb Clinical phenotypec Reference
CT1 (#5120) None None n.a. [17]
CT2 (#5119) None None n.a. [16]
CT3 (#5118) None None n.a. [16]
P1 (#6603) NDUFS8 R94C L/LL [16]
P2 (#6173) NDUFS1 R557X/D618N L/LD [17]
P3 (#5170) NDUFS2 R228Q HCEM [46]
P4 (#5866) NDUFV1 R59X/T423M MLM/LL [47]
P5 (#5175) NDUFS7 V122M L/LL [48]
P6 (#5171) NDUFV1 R59X/T423M MLM/LL [47]
a CT and P indicate control and patient cell lines, respectively. Numbers indicate the
designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders
(NCMD).
b Mutations are given at the protein level.
c Clinical phenotype: L/LD, Leigh syndrome and leukodystrophy; L/LL, Leigh syndrome
and Leigh-like syndrome; MLM, macrocephaly, leukodystrophy and myoclonic epilepsy;
HCEM, hypertrophic cardiomyopathy and encephalomyopathy. Abbreviations: n.a., not
appropriate.
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hearts, increases in complex I-mediated ROS productionwere found to
be accompanied by thiol modiﬁcations of matrix-facing complex I
subunits following ischemia reperfusion [21]. Finally, recent work
revealed that increases in mitochondrial ROS production can lead to
accelerated degradation of newly synthesized mitochondrial proteins
[27]. It was suggested that consequent down-regulation of the most
sensitive OXPHOS complexes may further increase mitochondrial
superoxide production, which is compatible with the progressive
nature of complex I deﬁciency.
In accordance with the above ﬁndings, antioxidants were found to
improve OXPHOS function in superoxide dismutase 2 null mice [28].
Furthermore, chronic antioxidant treatmentwas shown to increase CV
activity and ATP synthesis in cybrids containing themtDNA of patients
with the T8993GmtDNAmutation associated with impaired oxidative
phosphorylation in NARP (neuropathy, ataxia and retinitis pigmen-
tosa) andMILS (maternally inherited Leigh's syndrome) [29]. Likewise,
chronic oral administration of vitamin E prevented the loss of
mitochondrial function and reduced ROS-induced damage in aging
mice [30]. These beneﬁcial effects were paralleled by an increased
lifespan, better neurological performance and higher exploratory
activity. Regarding human complex I deﬁciency, patients have been
found to respond differentially to antioxidant treatment (e.g. Ref. [31]).
Together, these ﬁndings indicate that superoxide and derived ROS
may play an important role in the pathogenesis of disorders associated
with defects of the OXPHOS system. Here, we assessed the relationship
between cellular ROS levels and complex I expression and activity in
nDNA-inherited isolated complex I deﬁciency. The data presented
demonstrate that cellular ROS levels are signiﬁcantly increased inpatient
cells and that this increase is associated with variable decreases in the
amount and intrinsic catalytic activity of complex I. Most importantly,
our ﬁnding that chronic treatment with a vitamin E derivative (Trolox)
increases the amount of complex I might provide an experimental basis
for the use of antioxidants to treat complex I deﬁcient patients.
2. Materials and methods
2.1. Patient skin ﬁbroblasts
Fibroblasts were obtained from skin biopsies of three healthy subjects and six
complex I deﬁcient children in the age range of 0–5 years following informed parental
consent and according to the relevant Institutional Review Boards [32]. The deﬁciency
was conﬁrmed in both muscle tissue and cultured skin ﬁbroblasts. Patients were
screened for the presence of DNA alterations in each of the known nuclear-encoded
complex I genes and found to carry mutations in either the NDUFS1 (#6173), NDUFS2
(#5170), NDUFS7 (#5175), NDUFS8 (#6603) or NDUFV1 (#5866, #5171) gene (Table 1).
All patients were shown to be negative with respect to mitochondrial DNA alterations
associated with complex I deﬁciency. Fibroblasts were cultured in medium 199 with
Earle's salt supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin and
100 IU/ml streptomycin in a humidiﬁed atmosphere of 95% air and 5% CO2 at 37 °C. Cell
cycle analysis revealed no differences between the various cell lines [16].
2.2. Quantiﬁcation of cellular reactive oxygen species levels
Cellular reactive oxygen species levelswere quantiﬁedasdescribed previously [22,24].
Brieﬂy, ﬁbroblasts were incubated in HEPES–Tris medium (132 mM NaCl, 4.2 mM KCl,
1mMCaCl2,1mMMgCl2, 5.5mMD-glucose and 10mMHEPES, pH 7.4) containing 1 μM5-
(and -6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate (CM-H2DCFDA; Mole-
cular Probes) for 10 min at 37 °C. During this period, the acetate groups are cleaved by
intracellular esterases yielding dichlorodihydroﬂuorescein (CM-H2DCF), which is then
oxidized by oxidants to form highly ﬂuorescent dichloroﬂuorescein (CM-DCF). After
loading, the cells were thoroughly washed and transferred to the stage of an Oz confocal
microscope (Noran Instruments, Middleton, WI, USA). Routinely, CM-DCF ﬂuorescence
wasmonitoredduring 200 s at a 10 s-interval. After background correction, the rate of CM-
DCF ﬂuorescence increase during the ﬁrst 150 s was determined as a measure of the
cellular ROS level. On each measuring day, the average rate obtained with #5120 control
ﬁbroblastswas set at 100%, towhich all valueswere related. All recordingswere carried out
at minimal laser intensity using identical hardware settings.
2.3. Blue native PAGE, Western blot analysis and in-gel activity measurement
Cultured skin ﬁbroblasts were harvested by trypsinization, washed with ice-cold
phosphate-buffered saline (PBS; Braun, Melsungen, Germany) and resuspended(approx. 2×106 cells) in 100 μl ice-cold PBS. For preparation of a mitochondria-
enriched fraction, cells were incubated with 2 mg/ml digitonin (Biosciences Inc., La
Jolla, CA, USA) in a ﬁnal volume of 200 µl for 10 min on ice. Next, 1 ml ice-cold PBS was
added followed by centrifugation (5 min; 10,000 ×g; 4 °C). Mitochondrial pellets were
washed twice with 1 ml ice-cold PBS and stored overnight (−20 °C). Pellets were
solubilized in 100 μl ACBT buffer (Fluka, Steinheim, Germany) containing 1.5 M
aminocaproic acid and 75 mM Bis–Tris/HCl (pH 7.0). To extract mitochondrial protein
complexes, 20 μl 10% (w/v) β-lauryl maltoside was added and the solution was
incubated for 10 min on ice. After centrifugation (30 min; 10,000 ×g; 4 °C), 10 μl of BN
sample buffer (Biorad Laboratories, Hercules, CA, USA) was added to the supernatant.
Blue native PAGE, Western blotting using a monoclonal antibody against the NDUFA9
(39-kDa) subunit of complex I (Molecular Probes) at a dilution of 1:1000, and in-gel
activity measurement were performed as described previously [33]. For quantitative
analysis, gels were loaded with exactly 10 μg of mitochondrial protein.
2.4. Data analysis
After Western blotting, luminescent signals were quantitatively analyzed by
exposing illumination ﬁlms to the blots for different periods of time (5–180 s). Films
that displayed sub-maximal, non-saturated, signals were scanned using a G690 Imaging
Densitometer (Biorad). From these scans, the integrated optical density of each band
was determined and background corrected. The resulting numerical values were
normalized to those obtained with control cells on the same blot. For quantitative
analysis of in-gel activity, gels were scanned directly. Numerical results were visualized
using Origin Pro 7.5 (OriginLab Corp., Northampton, MA, USA) and presented as the
mean±SEM. Statistical differences were determined using either a two-population or
one-population Student's t-test (Bonferroni corrected).
2.5. Chemicals
Culturematerials were obtained from Invitrogen (Breda, The Netherlands), all other
reagents were from Sigma-Aldrich (St. Louis, MO, USA).
3. Results
3.1. Cellular ROS levels are decreased by the water-soluble vitamin E
derivative Trolox
To quantify cellular ROS levels, ﬁbroblasts of a healthy control sub-
ject (#5120) were loaded with non-ﬂuorescent CM-H2DCFDA (5-(and
-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate; 1 µM) for
10 min, thoroughly washed to remove excess CM-H2DCFDA, and
monitored for the conversion of intracellularly trapped CM-H2DCF into
ﬂuorescent CM-DCF. Video-imaging microscopy revealed that CM-DCF
ﬂuorescencewas uniformly distributed throughout the cell (Fig.1A) and
increased linearly with time (Fig. 1B; open symbols). Importantly, this
linearity indicates that the amount of CM-H2DCF is not rate-limiting
[22,24]. Acute application of Trolox (6-hydroxy-2,5,7,8-tetramethylchro-
man-2-carboxylic acid) instantaneously decreased the rate of CM-DCF
formation by ~50% (Fig. 1B; ﬁlled symbols and inset). We showed pre-
viously that acute application of exogenous hydrogen peroxide (H2O2)
readily increased the rate of CM-DCF formation in human skin
Fig. 1. Effect of acute and chronic Trolox treatment on cellular ROS levels. (A) Fluorescence images of control ﬁbroblasts (#5120) at the indicated time points after removal of non-
hydrolyzed CM-H2DCFDA, showing the intracellular conversion of non-ﬂuorescent CM-H2DCF into ﬂuorescent CM-DCF. Fluorescence at time zero originates from CM-DCF produced
during the loading period. The white circle represents the region of interest used for quantitative analysis. (B) Effect of acute application of Trolox on the rate of CM-H2DCF oxidation
in control ﬁbroblasts. Trolox (0.5 mM) was added at the indicated time point (black bar). Lines indicate a linear ﬁt to the time course before (open symbols; slope=0.00181±3.4·10−5,
R=0.99, pb0.0001) and after (ﬁlled symbols; slope=8.5·10−4±5.2·10−5,·R=0.98, pb0.0001) addition of Trolox. The inset shows that Trolox decreased the rate of CM-DCF formation by
50% (N=5 cells). (C) Rate of CM-DCF formation in control cells cultured in the absence (open bar; N=19 cells) and presence (black bar; N=16 cells) of 0.5 mM Trolox for 96 h. (D) Rate
of CM-DCF formation following acute application of 1 mM hydrogen peroxide (H2O2) to the untreated (open bar; N=19 cells) and Trolox-treated (black bar; N=16 cells) cells.
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increase in the rate of CM-DCF formation, healthy control cells were
cultured in thepresenceof Trolox (0.5mM) for96hand loadedwithCM-
H2DCF. The rate of CM-DCF formationwas signiﬁcantly lower in Trolox-
treated cells (Fig. 1C; ﬁlled bar). Subsequent addition of a high
concentration of H2O2 (1 mM) increased the rate of CM-DCF formation
23-fold in vehicle treated cells (Fig. 1D; white bar). In contrast, H2O2
application only 12-fold increased the rate of CM-DCF formation inTrolox-treated cells (Fig. 1D; black bar). These ﬁndings demonstrate the
effectiveness of Trolox as an antioxidant in human skin ﬁbroblasts.
3.2. Trolox normalizes increased cellular ROS levels in complex I deﬁcient
patient ﬁbroblasts
The rate of CM-DCF ﬂuorescence increase did not signiﬁcantly
differ between the three healthy control cell lines (100±2%, 100±11%
Fig. 3. Effect of Trolox on complex I amount and activity in control ﬁbroblasts. (A) Inset
depicts mitochondrial protein complexes separated by blue native PAGE and subjected
to Western blot detection (WB) of complex I and in-gel activity (IGA) measurement.
Complex I was visualized using a monoclonal antibody against the 39-kDa (NDUFA9)
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cells), respectively). In all patient cell lines analyzed, the rate of CM-
DCF formation was signiﬁcantly higher than in each of the controls
(Fig. 2; open bars). Chronic treatment with Trolox (0.5 mM) for 96 h
signiﬁcantly decreased the rate of CM-DCF formation in both healthy
control cells and complex I deﬁcient patient cells (ﬁlled bars).
3.3. Amount and activity of complex I are variably decreased in complex I
deﬁcient patient ﬁbroblasts
To assess the cellular and molecular basis of the decrease in
complex I activity in patient ﬁbroblasts, we performed blue native
PAGE followed by Western-blot analysis (WB) and in-gel activity
measurement (IGA) [13,23,34]. As shown in the inset of Fig. 3A (upper
left lane) probing of the WB with a monoclonal antibody against the
NDUFA9 (39-kDa) subunit of complex I revealed a band of ~1 MDa. A
signal at the same height appeared in the IGA assay (lower left lane),
demonstrating that the WB band represents the fully assembled,
catalytically active complex. First, the linearity of the IGA assay was
determined in a dilution experiment using a mitochondrial fraction of
healthy control cells (#5120). The data was expressed as % of the
integrated optical density of the band obtained with 10 µg of protein
for both the WB and the IGA (Fig. 3A; grey symbol labeled 10 µg). The
normalized IGA and WB values displayed a linear relationship with a
slope of 1.01±0.03 (R=0.998, pb0.0001) (Fig. 3A; grey symbols). In the
remainder of this study, blue native PAGE gels were routinely loaded
with exactly 10 µg of sample protein and the integrated optical
densities obtained with mitochondria-enriched fractions of control
and patient cell lines were expressed relative to that of control #5120
present on the same gel.
Three healthy control cell lines expressed only the fully assembled,
catalytically active complex. Analysis of the patient cell lines showed
the presence of a catalytically active complex, the size of which did not
differ from control. Fig. 3A (open symbols) shows that in all patient
cell lines the amount of active complex was signiﬁcantly lower than
control (#5120). Furthermore, this ﬁgure shows that in two patient
cell lines (#5171 and #5866) the activity of this complex was con-Fig. 2. Effect of Trolox on cellular ROS levels in human ﬁbroblasts. Patient ﬁbroblasts
displayed cellular ROS levels that were signiﬁcantly increased as compared to control
(open bars) and efﬁciently reduced by chronic Trolox treatment (0.5 mM, 96 h; closed
bars). Note that chronic Trolox also decreased the cellular ROS level in control cell line
#5120. The data presented are from individual cells measured on 2–6 days. On each
measuring day, the mean value obtained with vehicle-treated #5120 control cells
was set at 100%, to which all values obtained that day including those obtained
with the #5120 control cells themselves were related. Depicted are the mean±SEM of
236 (#5120; bar a), 117 (#6603; bar b), 87 (#6173; bar c), 124 (#5170; bar d), 76 (#5175;
bar e) and 78 (#5171; bar f) vehicle-treated cells and 159 (#5120), 31 (#6603), 56
(#6173), 62 (#5170), 47 (#5175) and 32 (#5171) Trolox-treated cells. ⁎Signiﬁcantly
different from the indicated vehicle-treated condition (pb0.05).
subunit. To determine the relationship between the WB signal and the IGA signal, a
dilution series was prepared from a mitochondria-enriched fraction of control cell line
#5120 (grey symbols; numerals indicate micrograms of protein). The integrated optical
density obtained with 10 µg of sample protein was set at 100%, to which all other values
were related. The continuous line represents a linear ﬁt to the data and was statistically
identical to the line of identity (R=0.998, slope=1.01±0.03, intercept=−2.32±2.81%,
pb0.0001). Open circles represent the WB and IGA values obtained with 10 µg of
protein from the indicated patient cell line relative to those obtained with 10 µg of
healthy control protein (#5120). Chronic Trolox treatment (0.5 mM, 96 h) increased the
expression and activity of fully assembled complex I in healthy control cells (inset;
upper and lower right lane). Closed symbols represent the WB and IGA values obtained
with the indicated cell lines after chronic treatment with Trolox. (B) Ratio between the
Trolox-induced increase in complex I activity and the corresponding increase in
complex I amount (Δactivity/Δamount) as a measure of the intrinsic catalytic activity of
the complex in control cell lines (closed bars) and patient cell lines (open bars). The
average ratio obtained with control cell line #5120 was set at 100% (dotted line), to
which all values including those of control cell line #5120 itself were related. The
data presented are from 8 (#5120), 1 (#5119), 2 (#5118), 1 (#6173), 2 (#6603), 1 (#5170),
3 (#5866), 2 (#5171), and 4 (#5175) independent experiments. Error bars represent
standard deviation (nN2 experiments) or difference between duplicate values (n=2).siderably less than expected on the basis of its amount (i.e. both data
points were well below the line of identity obtained with control cell
line #5120).
3.4. Trolox increases the amount and activity of complex I in control and
patient ﬁbroblasts
Chronic treatment with Trolox markedly increased complex I
amount and activity in control ﬁbroblasts (Fig. 3A; inset, upper and
lower right lane). The regression line for the Trolox-treated healthy
control cells (Fig. 3A; #5120, black symbols) had a slope of 0.86±0.11
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identity, indicating that the intrinsic catalytic activity of the wild-type
complexes was not altered.
Similarly to control ﬁbroblasts, all patient ﬁbroblasts displayed an
increase in fully assembled, catalytically active complex. Control
experiments with isolated heart mitochondria demonstrated that
acute exposure to Trolox (0.5 mM, 15 min) did not alter the amount
and/or in-gel activity of the active complex (not shown). This result
makes it highly unlikely that Trolox exerts its effect by stabilizing the
complex during β-lauryl maltoside extraction and subsequent native
electrophoretic separation and/or increasing its in-gel activity. Calcula-
tion of the ratio between the Trolox-induced increase in complex I
activity (ΔActivity) and the corresponding increase in complex I amount
(ΔAmount) revealed that compared to control #5120, for which the
average ratio was set at 100%, two other control cell lines behaved
similarly. In contrast, for all patient cell lines the increase in complex I
activity was less than the increase in complex I amount. This indicates
that all patient complexes display a reduced intrinsic catalytic activity,
which was smallest in patient cell line #5175 and largest in patient cell
line #6173 (Fig. 3B). Furthermore, comparison of Fig. 3A and B shows
that patient cell lines with the largest intrinsic catalytic defect (#6173,
#6603, #5170) display the lowest amount of fully assembled, catalyti-
cally active complex.
4. Discussion
Pathogenic mutations in nDNA-encoded subunits of mitochondrial
complex I lead to a reduction in its total cellular activity and are
associated with a broad spectrum of clinical manifestations occurring
shortly after birth or during early childhood [2,3,5,6]. Here we
analyzed cultured skin ﬁbroblasts of six childrenwith disease-causing
mutations in nDNA-encoded complex I subunits and show that they
expressed catalytically active holo complex I. Although the MWof this
holocomplex did not differ from control, its amount and intrinsic
catalytic activity were decreased to a variable extent.
Extrapolation of the results obtained in this study to the whole
population of isolated complex I deﬁcient patients means that some
patients may have primarily a relatively mild expression problem
(#5175 of this study), other patients may have a relatively mild
expression problem combined with a relatively mild intrinsic catalytic
problem (#5171 and#5866of this study), and again other patientsmay
have both a severe expression problem and a severe intrinsic catalytic
problem (#6173, #6603 and #5170 of this study). The most important
consequence of our ﬁndings is that therapeutic strategies aimed at
improving the expression of complex I in nDNA-inherited complex I
deﬁciency are only meaningful if the fully assembled complex has a
substantial residual activity. In this context, our resultsmayexplain the
observation that complex I deﬁcient patients respond differentially to
antioxidant treatment [31]. Taken together, the data obtained with
Troloxmay provide an experimental basis for antioxidant treatment of
complex I deﬁcient patients in which primarily the expression of
complex I is reduced rather than the activity per complex.
The present study demonstrates that blue native gel electrophoresis
in combination with Western blotting and in-gel activity measurement
is a powerful tool to establish the relative contribution of an expression
defect and an intrinsic catalytic defect to the decrease in total cellular
complex I activity in isolated human complex I deﬁciency. All three
control cell lines harbored the fully assembled, catalytically active
complex and a line of identity was observed between amount and
activity when expressed relative to the values obtained with control cell
line #5120, indicating that the intrinsic catalytic activity was the same
for the three control cell lines (not shown). Trolox treatment signiﬁcantly
increased both parameters and also in this case the obtained data points
lie on the line of identity. The latter result indicates that Trolox does not
alter the intrinsic catalytic activity of the complex and, thus, primarily
acts by increasing its expression. All six patient cell lines expressedsigniﬁcantly less active complex than the control. Importantly, control
experiments revealed that this reduction was not due to experimental
procedures because Western blot analysis of mitochondrial enriched
fractions and whole-cell homogenates under denaturating conditions
conﬁrmed that all six patient cell lines contained signiﬁcantly less
39 kDa subunit than control (see also Refs. [35] and [36]).
In agreement with our results, a recent study revealed that the
NDUFS1-Q522K mutation is associated with a marked reduction in
complex I amount and activity and a signiﬁcant increase in ROS [14].
Most importantly, these patient cells showed an enhanced mitochon-
drial susceptibility to ROS damage. Here, we made use of the ability of
Trolox to increase the amount of active complex I to identify patient
cell lines with an intrinsic catalytic defect and to determine the
severity of this defect. In all but one case (#5175), Trolox treatment
increased the in-gel activity with a smaller factor than the amount of
active complex, indicating the presence of a catalytic defect. Three of
the patient cell lines also contained a catalytically inactive complex of
smaller size, the amount of which was also increased by Trolox.
Thus far, only few studies have addressed the effect of pathogenic
mutations on the intrinsic catalytic activity of complex I. Two of the
mutations studied here, NDUFS2-R228Q (#5170) and NDUFS7-V122M
(#5175), have been analyzed in great detail in the yeast Yarrowia
lipolytica [15,37]. In contrast to our ﬁndings, these mutations did not
reduce complex I content. Moreover, the NDUFS2-R228Q mutation did
not alter the intrinsic catalytic activity of the complex,whereas in case of
the NDUFS7-V122M mutation this activity was virtually halved. In
contrast, the NDUFS7-V122M mutation, as well as the NDUFV1-T423M
mutation, had no major effect on the catalytic activity of complex I in
Neurospora crassa, [38]. Therefore it was concluded that diminished
formation and or stability of the complex are themajor factors in cellular
complex I deﬁciency. Both groups used essentially the same analysis
methods, suggesting that the observed discrepancies are due to the use
of different model systems. In the present study we used the original
patient cell lines and again obtained yet another result with these
mutations. Taken together, these ﬁndings stress the importance of the
model system that is chosen for the analysis of pathogenic mutations.
Theﬁvemutated subunits investigatedconstitutepartof the “catalytic
core” of complex I, which furthermore contains the nDNA-encoded
NDUFV2 and NDUFS3 subunits and seven mtDNA-encoded subunits,
[39]. Because the ﬁve subunits all contain one or more iron-sulfur
clusters, it remains to be established whether the variable decreases in
intrinsic catalytic activity are due to amore or lesser efﬁcient transport of
electrons through the mutated forms of these subunits.
It also remains to be determined whether the increased ROS in
patient cells are derived from superoxide generated by abnormal
functioning complex I or originate from other enzyme systems as a
consequence of increased NADH and/or ambient oxygen levels [40].
A further question that needs to be resolved is whether the lower
complex I amount results from the use of imperfectly ﬁtting building
blocks, whichmight slow down the assembly process or accelerate the
breakdown process, or whether it is a consequence of, for instance,
ROS damage. The data obtained with Trolox suggest that at least part
of the decrease in complex I amount can be explained by an increase in
cellular ROS.
4.1. Evidence that complex I expression may be controlled by the cell's
oxidative balance
Trolox is a phenolic antioxidant with a chromane structure similar
to vitamin E but without the hydrophobic polyisoprenoid tail of the
latter [41]. Vitamin E exerts its antioxidant action through the
phenolic hydroxyl group, which readily donates its hydrogen to, for
instance, polyunsaturated fatty acid peroxyl radicals, thereby forming
a stable lipid species [42]. In this reaction, vitamin E is converted into a
relatively unreactive free radical. In vitro evidence suggests that this
radical can be regenerated by ascorbate, resulting in the formation of
858 W.J.H. Koopman et al. / Biochimica et Biophysica Acta 1777 (2008) 853–859an ascorbyl radical [42]. Trolox treatment increased the amount of fully
assembled, catalytically active, complex I in healthy control ﬁbroblasts.
Thismay suggest that total cellular complex I activity is controlled by the
cell's oxidative balance primarily through regulation of its amount.
Using bovine heart submitochondrial particles, it was shown that the
decrease in complex I activity inducedbyperoxidationof cardiolipinwas
reversed upon addition of exogenous cardiolipin, indicating an effect of
peroxidized cardiolipin on the activity per complex rather than on its
amount [43]. It has been demonstrated that depletion of cardiolipin also
causes an increase in ROS production [44], possibly leading to oxidative
damage of complex I [25–27]. Similarly, enhanced ROS generation was
found to be associated with thiol modiﬁcations in several matrix-facing
subunits of complex I and a reduction in complex I-linked respiration
[21]. It remains to be ﬁrmly established whether Trolox acts by directly
reversing ROS damage in patient ﬁbroblasts. Recent work has shown
that overexpression of Mitofusin-2 (Mfn2) increased not only the
complexity of the mitochondrial network but also the expression of
complex I subunits, suggesting a link between mitochondrial morphol-
ogy and complex I expression [36,45]. An interesting possibility might
therefore be that Trolox acts through a change inmitochondrial network
morphology to alter complex I expression.
4.2. Conclusions
This study provides evidence that the amount of active complex I is
under regulatory control of the cell's oxidative balance. Results
obtained with the antioxidant Trolox revealed that apart from the
amount also the intrinsic activity of the complex can be signiﬁcantly
decreased in nDNA-inherited isolated complex I deﬁciency. The
ﬁnding that Trolox treatment increased the amount of complex I
might provide an experimental basis for the use of antioxidants to
mitigate the deﬁciency. However, it is to be expected that such a
treatment is only beneﬁcial to patientswith a predominant expression
rather than intrinsic catalytic defect of the complex.
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